Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat
09:24am, Wednesday, 05'th May 2021
Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q1 2021 Results - Earnings Call Transcript
03:05pm, Tuesday, 04'th May 2021
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q1 2021 Results - Earnings Call Transcript
Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021
07:30am, Wednesday, 21'st Apr 2021
PARSIPPANY, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets
Pacira BioSciences Announces Investment in Spine BioPharma
07:30am, Tuesday, 20'th Apr 2021
-- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease -- PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industr
Complaint challenges the American Society of Anesthesiologists for promoting biased, analytically misguided studies in its journal, on its website, and through CME activity Complaint challenges the Am
Pacira (PCRX) Down 3.6% Since Last Earnings Report: Can It Rebound?
12:41pm, Saturday, 27'th Mar 2021
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
After a Label Expansion, Is This Under-the-Radar Biotech a Buy?
06:25am, Saturday, 27'th Mar 2021
This healthcare stock just got great news from the Food and Drug Administration.
Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients
10:36am, Tuesday, 23'rd Mar 2021
The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.
-- EXPAREL is the first and only FDA-approved long-acting local analgesic for children aged six and over –-- Conference call tomorrow at 8:30 a.m. ET -- PARSIPPANY, N.J., March 22, 2021 (GLOBE NEWSW
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
09:52am, Saturday, 20'th Mar 2021
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the bigges
Pacira BioSciences Reports Preliminary Net Product Sales of $36.2 Million for February 2021
08:00am, Tuesday, 09'th Mar 2021
-- EXPAREL average daily sales at 103% of the prior year for the month of February 2021 -- PARSIPPANY, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry le
Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference
07:30am, Wednesday, 03'rd Mar 2021
PARSIPPANY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Barclays Global Healthcare Conference at 10:55 AM ET on Tu
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
09:51am, Friday, 26'th Feb 2021
Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q4 2020 Results - Earnings Call Transcript
03:22pm, Thursday, 25'th Feb 2021
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q4 2020 Results - Earnings Call Transcript
Pacira (PCRX) Q4 Earnings Beat Estimates
10:39am, Thursday, 25'th Feb 2021
Pacira (PCRX) delivered earnings and revenue surprises of 6.10% and -0.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
